Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication.
Welcome to another edition of "3 Things In Biotech," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research.
Progenics has a set back with the FDA
Company: Progenics Pharmaceuticals (PGNX)
Therapy: Iobenguane I-131
Disease: Pheochromocytoma
News: PGNX announced that the FDA has delayed the PDUFA date for its lead agent Azedra by three months, placing the action date on July 30. This was due to additional CMC information that